CVAC News and Press, CureVac N.V. From 08/10/21

The short-term thesis for investing in Moderna is the belief that the company will continue to profit from its COVID-19 vaccine because of booster shots. The long-term thesis for investing in Moderna is the belief that the company has more success to come from a promising vaccine...

Amid rising cases of Delta variant of coronavirus, the U.S. Centers for Disease Control and Prevention (CDC) advisory panel will meet on Friday to discuss considerations for booster doses of COVID-19 vaccines, Reuters reports. The meeting is also expected to discuss updates on additional dose...

LarisaBozhikova/iStock via Getty Images Amid ongoing discussions regarding the necessity of booster shots for prevention of COVID-19, Biden administration health officials believe that vulnerable populations will need booster shots, The Washington Post reports. Senior officials expect that pe...

Scott Olson/Getty Images News With the spread of the highly transmissible Delta variant of the coronavirus, the effectiveness of the COVID-19 vaccine from Pfizer ([[PFE]] +0.6%)/BioNTech ([[BNTX]] +0.5%) has dropped to 39% in Israel, the country’s Ministry of Health said on Thursday, a...

Biotech stocks had a muted first half with the S&P Biotech Index down year-to-date, and more than 20% lower from its mid-February peak. The decline in biotech stocks coincided with a spike in interest rates and stabilizing interest rates can provide a boost to valuations. M&am...

naphtalina/iStock via Getty Images COVID-19-related headlines dominated the holiday-shortened week as the Delta variant of the virus renewed pandemic fears across the globe. Meanwhile, with a ~1.3% gain over the past five-day period, the S&P 500 Healthcare Index outper...

CureVac (NASDAQ: CVAC) surprised investors a few weeks ago when it announced disappointing data from a trial of its mRNA vaccine candidate. Many expected the German biotech would follow in the footsteps of fellow mRNA vaccine makers Pfizer and Moderna . These market leaders ...

Scott Olson/Getty Images News Israel has reported a drop in the efficacy of the Pfizer (PFE) / BioNTech (BNTX) COVID-19 vaccine in protecting from infections and symptomatic illness, Reuters reports. The decline coincided with the spread of the Delta variant and the end of social distancing r...

On June 30, CureVac (NASDAQ: CVAC) announced final late-stage clinical data for its mRNA coronavirus vaccine candidate CVnCoV. The data was disappointing, to put it mildly, and the stock sold off more than 10% in the after-hours trading session to $66 apiece. Nobod...

CureVac (NASDAQ: CVAC) is working on mRNA coronavirus vaccine candidates. If it's successful, mRNA vaccine giants Moderna and Pfizer will face competition. In this Motley Fool Live video recorded on June 22 , healthcare and cannabis bureau editor and analyst Olivia Z...